XRTX
XORTX Therapeutics Inc.
Price Chart
Latest Quote
$0.49
Current Price| Previous Close | $0.50 |
| Open | $0.49 |
| Day High | $0.51 |
| Day Low | $0.49 |
| Volume | 33,138 |
Stock Information
| Shares Outstanding | 6.96M |
| Total Debt | $59K |
| Cash Equivalents | $1.19M |
| Net Income | $-1.94M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.41M |
| EPS (TTM) | $-0.40 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.01 |
| Debt to Earnings | -0.01 |
| Current Ratio | 3.53 |
| Quick Ratio | 3.29 |
| Return on Equity | -99.30% |
| Avg FCF Growth | -5.77% |
| FCF Yield | -108.97% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.49 | 33,138 |
| 2026-01-30 | $0.50 | 45,800 |
| 2026-01-29 | $0.49 | 59,000 |
| 2026-01-28 | $0.51 | 35,000 |
| 2026-01-27 | $0.54 | 23,400 |
| 2026-01-26 | $0.54 | 21,200 |
| 2026-01-23 | $0.57 | 11,200 |
| 2026-01-22 | $0.56 | 18,700 |
| 2026-01-21 | $0.58 | 16,200 |
| 2026-01-20 | $0.57 | 61,900 |
| 2026-01-16 | $0.57 | 15,900 |
| 2026-01-15 | $0.58 | 48,900 |
| 2026-01-14 | $0.58 | 9,000 |
| 2026-01-13 | $0.60 | 25,400 |
| 2026-01-12 | $0.58 | 12,300 |
| 2026-01-09 | $0.58 | 7,900 |
| 2026-01-08 | $0.59 | 13,800 |
| 2026-01-07 | $0.60 | 25,900 |
| 2026-01-06 | $0.60 | 32,000 |
| 2026-01-05 | $0.61 | 117,100 |
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.
đ° Latest News
XORTX Therapeutics Says Published Research Supports Company Approach to Gout Treatment
MT Newswires âĸ 2026-01-02T12:24:37ZXORTX Therapeutics Down Near 10% In US Premarket As Prices US$1.1 Million Registered Direct Offering
MT Newswires âĸ 2025-10-21T12:13:34ZMT Newswires Canada Overnight Stocks To Watch: Allied Gold; Lithium Americas; XORTX Therapeutics
MT Newswires âĸ 2025-10-21T01:00:12ZXORTX Therapeutics Jumps 45% on US$3 Million Deal to Buy Renal Program From Vectus Biosystems
MT Newswires âĸ 2025-10-17T11:44:38ZXORTX Therapeutics Edging Up In US Premarket As Initiates IND Preparation for XORLO in Gout Program
MT Newswires âĸ 2025-09-03T12:17:22ZIncome Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $4,118,319 | $6,045,986 | $10,290,606 | $2,910,605 |
| Other Income Expense | $683,065 | $3,634,378 | $2,468,135 | $1,335,782 |
| Net Non Operating Interest Income Expense | $121,908 | $253,543 | $103,589 | $-4,451 |
| Total Other Finance Cost | $-121,908 | $-253,543 | $-103,589 | $4,451 |
| Operating Expense | $4,118,319 | $6,045,986 | $10,290,606 | $2,910,605 |
| Other Operating Expenses | $1,533,490 | $1,259,861 | $1,071,775 | $602,570 |
| General And Administrative Expense | $2,283,725 | $2,227,716 | $2,398,867 | $1,616,193 |
| Interest Expense | - | - | $0 | $4,391 |
| Interest Expense Non Operating | - | - | $0 | $4,391 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-3,313,346 | $-2,158,065 | $-7,718,882 | $-1,579,274 |
| Net Interest Income | $121,908 | $253,543 | $103,589 | $-4,451 |
| Normalized Income | $-3,996,411 | $-5,792,443 | $-10,187,017 | $-2,915,056 |
| Net Income From Continuing And Discontinued Operation | $-3,313,346 | $-2,158,065 | $-7,718,882 | $-1,579,274 |
| Net Income Common Stockholders | $-3,313,346 | $-2,158,065 | $-7,718,882 | $-1,579,274 |
| Net Income | $-3,313,346 | $-2,158,065 | $-7,718,882 | $-1,579,274 |
| Net Income Including Noncontrolling Interests | $-3,313,346 | $-2,158,065 | $-7,718,882 | $-1,579,274 |
| Net Income Continuous Operations | $-3,313,346 | $-2,158,065 | $-7,718,882 | $-1,579,274 |
| Pretax Income | $-3,313,346 | $-2,158,065 | $-7,718,882 | $-1,579,274 |
| Special Income Charges | $-279,031 | $0 | $-926,456 | $-1,288,236 |
| Operating Income | $-4,118,319 | $-6,045,986 | $-10,290,606 | $-2,910,605 |
| Depreciation Amortization Depletion Income Statement | $117,274 | $139,694 | $58,146 | $14,266 |
| Depreciation And Amortization In Income Statement | $117,274 | $139,694 | $58,146 | $14,266 |
| Amortization Of Intangibles Income Statement | $31,070 | $66,632 | $17,077 | $14,266 |
| Depreciation Income Statement | $86,204 | $73,062 | $41,069 | $0 |
| Interest Income | - | - | $101,367 | - |
| Interest Income Non Operating | - | - | $101,367 | - |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.15 | $-1.09 | $-4.71 | $-1.20 |
| Basic EPS | $-1.15 | $-1.09 | $-4.71 | $-1.20 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,684,110 | $-9,540,670 | $-12,700,595 | $-4,232,121 |
| Total Unusual Items | $683,065 | $3,634,378 | $2,468,135 | $1,335,782 |
| Total Unusual Items Excluding Goodwill | $683,065 | $3,634,378 | $2,468,135 | $1,335,782 |
| Reconciled Depreciation | $117,274 | $139,694 | $58,146 | $14,266 |
| EBITDA (Bullshit earnings) | $-4,001,045 | $-5,906,292 | $-10,232,460 | $-2,896,339 |
| EBIT | $-4,118,319 | $-6,045,986 | $-10,290,606 | $-2,910,605 |
| Diluted Average Shares | $2,878,514 | $1,981,734 | $1,479,913 | $1,094,182 |
| Basic Average Shares | $2,878,514 | $1,981,734 | $1,479,913 | $1,094,182 |
| Diluted NI Availto Com Stockholders | $-3,313,346 | $-2,158,065 | $-7,718,882 | $-1,579,274 |
| Restructuring And Mergern Acquisition | $279,031 | $0 | $926,456 | $1,288,236 |
| Gain On Sale Of Security | $962,096 | $3,634,378 | $3,394,591 | $2,624,018 |
| Amortization | $31,070 | $66,632 | $17,077 | $14,266 |
| Research And Development | $183,830 | $2,418,715 | $6,761,818 | $677,576 |
| Selling General And Administration | $2,283,725 | $2,227,716 | $2,398,867 | $1,616,193 |
| Other Gand A | $1,993,055 | $1,927,326 | $1,788,355 | $1,170,404 |
| Salaries And Wages | $290,670 | $300,390 | $610,512 | $445,789 |
| Impairment Of Capital Assets | - | - | - | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $3,153,429 | $4,466,772 | $6,796,977 | $13,000,472 |
| Total Assets | $4,094,527 | $5,467,964 | $12,374,026 | $17,381,920 |
| Total Non Current Assets | $1,417,829 | $1,399,181 | $1,478,458 | $1,469,190 |
| Non Current Accounts Receivable | $1,200,000 | $1,200,000 | $1,185,946 | $1,267,065 |
| Goodwill And Other Intangible Assets | $183,108 | $175,254 | $199,834 | $202,125 |
| Other Intangible Assets | $183,108 | $175,254 | $199,834 | $202,125 |
| Current Assets | $2,676,698 | $4,068,783 | $10,895,568 | $15,912,730 |
| Current Deferred Assets | $0 | $323,441 | $0 | $0 |
| Prepaid Assets | $185,412 | $236,966 | $379,620 | $1,002,215 |
| Receivables | $17,637 | $60,711 | $81,752 | $40,654 |
| Accounts Receivable | $17,637 | $60,711 | $81,752 | $40,654 |
| Cash Cash Equivalents And Short Term Investments | $2,473,649 | $3,447,665 | $10,434,196 | $14,869,861 |
| Cash And Cash Equivalents | $2,473,649 | $3,447,665 | $10,434,196 | $14,869,861 |
| Cash Equivalents | $2,419,963 | $3,352,666 | $6,610,979 | $0 |
| Cash Financial | $53,686 | $94,999 | $3,823,217 | $14,869,861 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $38,785 | $11,510 | $77,599 | $0 |
| Current Debt And Capital Lease Obligation | $38,785 | $11,510 | $66,090 | - |
| Long Term Debt And Capital Lease Obligation | - | $0 | $11,509 | $0 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $757,990 | $825,938 | $5,377,215 | $4,179,323 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $3,865,912 | $3,626,375 |
| Current Liabilities | $757,990 | $825,938 | $1,511,303 | $552,948 |
| Other Current Liabilities | $572,000 | $531,000 | - | - |
| Payables And Accrued Expenses | $147,205 | $283,428 | $1,445,213 | $552,948 |
| Payables | $84,020 | $195,814 | $1,293,807 | $323,961 |
| Accounts Payable | $84,020 | $195,814 | $1,293,807 | $323,961 |
| Derivative Product Liabilities | - | $531,000 | $3,854,403 | $3,626,375 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $3,336,537 | $4,642,026 | $6,996,811 | $13,202,597 |
| Total Equity Gross Minority Interest | $3,336,537 | $4,642,026 | $6,996,811 | $13,202,597 |
| Stockholders Equity | $3,336,537 | $4,642,026 | $6,996,811 | $13,202,597 |
| Other Equity Interest | $6,063,824 | $5,493,003 | $6,221,904 | $5,016,340 |
| Gains Losses Not Affecting Retained Earnings | $-52,605 | $-52,605 | $-52,605 | $75,540 |
| Other Equity Adjustments | $-52,605 | $-52,605 | $-52,605 | $75,540 |
| Retained Earnings | $-21,168,253 | $-17,854,907 | $-15,696,842 | $-7,977,960 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $3,481,375 | $1,998,848 | $1,670,076 | $1,443,297 |
| Share Issued | $3,481,375 | $1,998,848 | $1,670,076 | $1,443,297 |
| Tangible Book Value | $3,153,429 | $4,466,772 | $6,796,977 | $13,000,472 |
| Invested Capital | $3,336,537 | $4,642,026 | $6,996,811 | $13,202,597 |
| Working Capital | $1,918,708 | $3,242,845 | $9,384,265 | $15,359,782 |
| Capital Lease Obligations | $38,785 | $11,510 | $77,599 | $0 |
| Total Capitalization | $3,336,537 | $4,642,026 | $6,996,811 | $13,202,597 |
| Capital Stock | $18,493,571 | $17,056,535 | $16,524,354 | $16,088,677 |
| Common Stock | $18,493,571 | $17,056,535 | $16,524,354 | $16,088,677 |
| Current Capital Lease Obligation | $38,785 | $11,510 | $66,090 | $0 |
| Current Accrued Expenses | $63,185 | $87,614 | $151,406 | $228,987 |
| Net PPE | $34,721 | $23,927 | $92,678 | $0 |
| Accumulated Depreciation | $-200,209 | $-114,005 | $-40,943 | $0 |
| Gross PPE | $234,930 | $137,932 | $133,621 | $0 |
| Other Properties | $23,344 | $23,344 | $19,033 | - |
| Buildings And Improvements | $211,586 | $114,588 | $114,588 | $0 |
| Properties | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | - | $0 | $11,509 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-3,717,572 | $-6,629,528 | $-8,211,660 | $-4,832,852 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-3,678,648 | $-6,583,165 | $-8,165,959 | $-4,801,045 |
| Cash Flow From Continuing Operating Activities | $-3,678,648 | $-6,583,165 | $-8,165,959 | $-4,801,045 |
| Operating Gains Losses | $-721,896 | $-3,655,037 | $-2,466,925 | $-2,608,133 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-38,924 | $-46,363 | $-45,701 | $-31,807 |
| Investing Cash Flow | $-38,924 | $-46,363 | $-45,701 | $-31,807 |
| Cash Flow From Continuing Investing Activities | $-38,924 | $-46,363 | $-45,701 | $-31,807 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $3,500,542 | $0 | $4,999,640 | $18,072,228 |
| Financing Cash Flow | $2,779,509 | $-361,044 | $3,912,141 | $19,372,334 |
| Cash Flow From Continuing Financing Activities | $2,779,509 | $-361,044 | $3,912,141 | $19,372,334 |
| Net Other Financing Charges | $-667,883 | $-295,251 | $-1,067,153 | $-698,579 |
| Net Common Stock Issuance | $3,500,542 | $0 | $4,999,640 | $18,072,228 |
| Common Stock Issuance | $3,500,542 | $0 | $4,999,640 | $18,072,228 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-69,723 | $-66,089 | $-20,410 | $0 |
| End Cash Position | $2,473,649 | $3,447,665 | $10,434,196 | $14,869,861 |
| Beginning Cash Position | $3,447,665 | $10,434,196 | $14,869,861 | $134,516 |
| Effect Of Exchange Rate Changes | $-35,953 | $4,041 | $-136,146 | $195,863 |
| Changes In Cash | $-938,063 | $-6,990,572 | $-4,299,519 | $14,539,482 |
| Proceeds From Stock Option Exercised | $16,573 | $296 | $64 | $1,998,685 |
| Net Issuance Payments Of Debt | $-69,723 | $-66,089 | $-20,410 | $0 |
| Net Long Term Debt Issuance | $-69,723 | $-66,089 | $-20,410 | $0 |
| Long Term Debt Payments | $-69,723 | $-66,089 | $-20,410 | $0 |
| Net Intangibles Purchase And Sale | $-38,924 | $-42,052 | $-26,005 | $-31,807 |
| Purchase Of Intangibles | $-38,924 | $-42,052 | $-26,005 | $-31,807 |
| Net PPE Purchase And Sale | $0 | $-4,311 | $-19,696 | $0 |
| Purchase Of PPE | $0 | $-4,311 | $-19,696 | $0 |
| Change In Working Capital | $116,793 | $-1,030,741 | $1,473,762 | $-1,083,419 |
| Change In Payables And Accrued Expense | $-134,447 | $-1,194,436 | $892,265 | $-259,323 |
| Change In Prepaid Assets | $208,166 | $142,654 | $622,595 | $-794,713 |
| Change In Receivables | $43,074 | $21,041 | $-41,098 | $-29,383 |
| Changes In Account Receivables | $43,074 | $21,041 | $-41,098 | $-29,383 |
| Stock Based Compensation | $122,527 | $120,984 | $487,940 | $396,423 |
| Depreciation Amortization Depletion | $117,274 | $139,694 | $58,146 | $14,266 |
| Depreciation And Amortization | $117,274 | $139,694 | $58,146 | $14,266 |
| Amortization Cash Flow | $31,070 | $66,632 | $17,077 | $14,266 |
| Amortization Of Intangibles | $31,070 | $66,632 | $17,077 | $14,266 |
| Depreciation | $86,204 | $73,062 | $41,069 | - |
| Gain Loss On Investment Securities | $-756,074 | $-3,641,403 | $-2,460,534 | $-2,636,391 |
| Net Foreign Currency Exchange Gain Loss | $34,178 | $-13,634 | $-6,391 | $28,258 |
| Net Income From Continuing Operations | $-3,313,346 | $-2,158,065 | $-7,718,882 | $-1,579,274 |
| Other Non Cash Items | - | - | $3,702 | $59,092 |
| Provisionand Write Offof Assets | - | - | $0 | $0 |
| Asset Impairment Charge | - | - | $0 | $0 |